Trexquant Investment’s VYNE Therapeutics VYNE Stock Holding History

Trexquant Investment’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-214	Closed	-$151K	–	1332
2018 Q3	$151K	Buy	+214	New	+$132K	0.01%	863

Other funds holding VYNE

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Trexquant Investment's VYNE Position: Q4 2018 in Review

Trexquant Investment sold out of VYNE Therapeutics (VYNE) in Q4 2018, closing a stake of 214 shares — an estimated $151K sold.

Trexquant Investment first reported a position in VYNE in Q3 2018 and held it in 1 quarter. The position peaked at $151K in Q3 2018. 56 funds tracked by Wall St. Rank hold VYNE as of Q4 2018.

Trexquant Investment reported no remaining VYNE Therapeutics position as of Q4 2018 after selling out during the quarter.
Trexquant Investment sold 214 VYNE Therapeutics shares in Q4 2018, an estimated $151K.
Trexquant Investment first reported a position in VYNE Therapeutics in Q3 2018 and held it in 1 quarter.
Trexquant Investment's VYNE Therapeutics position peaked at $151K in Q3 2018.
56 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q4 2018.

Based on Trexquant Investment's 13F filing for Q4 2018, filed 13 Feb 2019.